PD 123319

• UNSPSC Description:

  PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

• Target Antigen:

  Angiotensin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cardiovascular Disease; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/pd-123319.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H]1CC2=C(N=CN2CC3=CC=C(N(C)C)C(C)=C3)CN1C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)O

• Molecular Weight:

  508.61

• References & Citations:

  [1]Blankley CJ, et al. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem. 1991 Nov;34(11):3248-60.|[2]Boulay G, et al. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa. Mol Pharmacol. 1992 Apr;41(4):809-15|[3]Estrup TM, et al. No effect of angiotensin II AT(2)-receptor antagonist PD 123319 on cerebral blood flow autoregulation. J Renin Angiotensin Aldosterone Syst. 2001 Sep;2(3):188-92.|[4]Brillante DG, et al. Effects of intravenous PD 123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin Angiotensin Aldosterone Syst. 2005 Sep;6(2):102-6.Acta Pharmacol Sin. 2024 Mar 15.|FASEB J. 2019 May;33(5):6254-6268. |Int Immunopharmacol. 2022 Jun 17;110:108921.|J Exp Med. 2022 Mar 7;219(3):e20211001.|Redox Biol. October 2021, 102115.|Rep Biochem Mol Biol. 2021 Jul;10(2):314-326.|Reports of Biochemistry and Molecular Biology. 2021 Aug.|SSRN. 13 Apr 2022.|FASEB J. 2018 Sep;32(9):5051-5062.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  130663-39-7